219 related articles for article (PubMed ID: 19306417)
41. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.
Townamchai K; Berkowitz R; Bhagwat M; Damato AL; Friesen S; Lee LJ; Matulonis U; O'Farrell D; Viswanathan AN
Gynecol Oncol; 2013 Apr; 129(1):18-21. PubMed ID: 23262378
[TBL] [Abstract][Full Text] [Related]
42. Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006.
Tchabo NE; McCloskey S; Mashtare TL; Andrews C; Singh AK; Mhawech-Fauceglia P; Odunsi K; Lele S; Jaggernauth W
Gynecol Oncol; 2009 Nov; 115(2):249-56. PubMed ID: 19692115
[TBL] [Abstract][Full Text] [Related]
43. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.
Fader AN; Boruta D; Olawaiye AB; Gehrig PA
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):21-9. PubMed ID: 19952744
[TBL] [Abstract][Full Text] [Related]
44. Should all patients with serous and clear cell endometrial carcinoma receive adjuvant chemotherapy?
Boren TP; Miller DS
Womens Health (Lond); 2010 Nov; 6(6):789-95. PubMed ID: 21118038
[TBL] [Abstract][Full Text] [Related]
45. The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma.
Kwon J; Ackerman I; Franssen E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1439-45. PubMed ID: 15275730
[TBL] [Abstract][Full Text] [Related]
46. Treatment of uterine papillary serous carcinoma with paclitaxel.
Ramondetta L; Burke TW; Levenback C; Bevers M; Bodurka-Bevers D; Gershenson DM
Gynecol Oncol; 2001 Jul; 82(1):156-61. PubMed ID: 11426978
[TBL] [Abstract][Full Text] [Related]
47. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
[TBL] [Abstract][Full Text] [Related]
48. Uterine papillary serous carcinoma pre-operatively diagnosed as endometrioid carcinoma: Is omentectomy necessary?
Peled Y; Aviram A; Krissi H; Gershoni A; Sabah G; Levavi H; Eitan R
Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):498-502. PubMed ID: 26235227
[TBL] [Abstract][Full Text] [Related]
49. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.
Le TD; Yamada SD; Rutgers JL; DiSaia PJ
Gynecol Oncol; 1999 Jun; 73(3):461-3. PubMed ID: 10366480
[TBL] [Abstract][Full Text] [Related]
50. Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.
Okazawa-Sakai M; Yokoyama T; Fujimoto E; Okame S; Shiroyama Y; Yokoyama T; Takehara K
Int J Clin Oncol; 2018 Aug; 23(4):715-725. PubMed ID: 29446043
[TBL] [Abstract][Full Text] [Related]
51. [Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
Xue DB; Ding LJ; Xia AL; Chen D; Xia HP; Teng XD; Xu ST; Zhang SJ; Ren XC
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):671-4. PubMed ID: 21176532
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study.
Mahdi H; Rose PG; Elshaikh MA; Munkarah A; Isrow D; Singh S; Waggoner S; Ali-Fehmi R; Morris RT; Harding J; DeBenardo R
Gynecol Oncol; 2015 Mar; 136(3):529-33. PubMed ID: 25575483
[TBL] [Abstract][Full Text] [Related]
53. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
Chambers JT; Chambers SK; Kohorn EI; Carcangiu ML; Schwartz PE
Gynecol Oncol; 1996 Mar; 60(3):438-42. PubMed ID: 8774654
[TBL] [Abstract][Full Text] [Related]
54. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC).
Price FV; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT
Gynecol Oncol; 1993 Dec; 51(3):383-9. PubMed ID: 8112650
[TBL] [Abstract][Full Text] [Related]
55. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy.
Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM
Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779
[TBL] [Abstract][Full Text] [Related]
56. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma.
Bancher-Todesca D; Neunteufel W; Williams KE; Prainsack D; Breitenecker G; Friedlander ML; Hacker NF
Gynecol Oncol; 1998 Dec; 71(3):344-7. PubMed ID: 9887228
[TBL] [Abstract][Full Text] [Related]
57. Uterine papillary serous carcinoma (pure and mixed type) compared with moderately and poorly differentiated endometrioid carcinoma. A clinicopathologic study.
Halperin R; Zehavi S; Langer R; Hadas E; Bukovsky I; Schneider D
Eur J Gynaecol Oncol; 2002; 23(4):300-4. PubMed ID: 12214728
[TBL] [Abstract][Full Text] [Related]
58. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
[TBL] [Abstract][Full Text] [Related]
59. Neoadjuvant chemotherapy in uterine papillary serous carcinoma.
Resnik E; Taxy JB
Gynecol Oncol; 1996 Jul; 62(1):123-7. PubMed ID: 8690284
[TBL] [Abstract][Full Text] [Related]
60. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma.
Solmaz U; Ekin A; Mat E; Gezer C; Dogan A; Biler A; Peker N; Hasdemir PS; Sanci M
Tumori; 2016 Dec; 102(6):593-599. PubMed ID: 27514313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
